Leerink Swann Resumes Anthera Pharma (ANTH) at Outperform
Tweet
Share
E-mailGet Alerts ANTH Hot Sheet
Price: $0.00 --0%
Rating Summary:
8 Buy, 3 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
8 Buy, 3 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Leerink Swann resumes coverage on Anthera Pharma (NASDAQ: ANTH) with a Outperform. PT $3.00.
The firm comments, "We foresee ANTH commercializing a promising and potentially differentiated immunotherapy in Blisibimod (B-mod [lupus]) if the company can successfully enroll pivotal CHABLIS-2 trial patients in order to achieve regulatory approvals in the US. Based on positive MEDACorp KOL feedback balanced by US enrollment concerns, we believe investors have oversold shares. KOL feedback was increasingly positive after each incremental B-mod PEARL-SC dataset, suggesting it may become a differentiated SLE therapy. Upside in ANTH shares could be driven by news of pivotal trial enrollment execution, differentiated datasets, signs of FDA flexibility related to SLE and growing Benlysta revenues."
For an analyst ratings summary and ratings history on Anthera Pharma click here. For more ratings news on Anthera Pharma click here.
Shares of Anthera Pharma closed at $0.69 yesterday.
The firm comments, "We foresee ANTH commercializing a promising and potentially differentiated immunotherapy in Blisibimod (B-mod [lupus]) if the company can successfully enroll pivotal CHABLIS-2 trial patients in order to achieve regulatory approvals in the US. Based on positive MEDACorp KOL feedback balanced by US enrollment concerns, we believe investors have oversold shares. KOL feedback was increasingly positive after each incremental B-mod PEARL-SC dataset, suggesting it may become a differentiated SLE therapy. Upside in ANTH shares could be driven by news of pivotal trial enrollment execution, differentiated datasets, signs of FDA flexibility related to SLE and growing Benlysta revenues."
For an analyst ratings summary and ratings history on Anthera Pharma click here. For more ratings news on Anthera Pharma click here.
Shares of Anthera Pharma closed at $0.69 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Anthropic CFO Krishna Rao is leading early IPO meetings with investors and has not discussed valuation - CNBC
- Axis Capital Limited Assumes Jubilant Foodworks Ltd (JUBI:IN) at Reduce (3)
- JPMorgan Assumes salesforce.com (CRM) at Overweight, 'Overblown Concerns'
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
